Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Astrocytoma/Astrocytic tumors
Stage/Subtype:  recurrent childhood cerebellar astrocytoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-23 of 23 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Everolimus in Treating Younger Patients With Recurrent or Progressive Low-Grade Gliomas
Status: Active
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Age: 3 to 21
Trial IDs: 120817, NCI-2012-02774, PNOC001, NCT01734512
Vaccine Therapy and Poly-ICLC in Treating Younger Patients with Recurrent Low-Grade Gliomas that Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 months to less than 22 years
Trial IDs: LGG Vaccine Trial, NCI-2016-00644, NCT02358187
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Recurrent or Refractory Tumors in the Brain and/or Spinal Cord
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: 03-133, NCI-2016-00928, MSKCC-03133, NCT00089245
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1414, NCI-2014-02410, NCT02323880
Phase I Trial of Afatinib in Pediatric Tumours
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 17
Trial IDs: 1200.120, NCI-2016-00936, 2014-002123-10, NCT02372006
Pomalidomide in Treating Younger Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 20
Trial IDs: PBTC-043, NCI-2014-02182, CC-4047-PBTC-043, PPBTC-043_R04PAPP01, NCT02415153
Vorinostat and Temsirolimus with or without Radiation Therapy in Treating Younger Patients with Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
Status: Active
Phase: Phase I
Type: Treatment
Age: 6 months to 21 years
Trial IDs: 2014-0135, NCI-2015-00817, NCT02420613
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: NLG2105, NCI-2015-01872, NCT02502708
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: AFLACST1501, NCI-2015-02256, IRB00083793, NCT02644460
iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 30
Trial IDs: GO29665, NCI-2016-00541, 2014-004685-25, NCT02639546
Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 2 to 22
Trial IDs: RXDX-101-03, NCI-2016-00924, NCT02650401
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 19 months to 20 years
Trial IDs: Glioma Vaccine, NCI-2016-00993, NCT01130077
Cyclophosphamide or Thalidomide after Stem Cell Transplant in Treating Younger Patients with Solid Tumors
Status: Active
Phase: No phase specified
Type: Treatment
Age: 5 to 21
Trial IDs: 201209088, NCI-2012-01541, NCT01661400
Vemurafenib in Treating Younger Patients with Recurrent or Refractory BRAFV600E-Mutant Brain Tumors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 25
Trial IDs: CC #120819, NCI-2014-00387, 076373, 092093, 120819 (PNOC 002), PNOC-002, NCT01748149
Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High Risk Solid Tumors or Lymphomas
Status: Active
Phase: No phase specified
Type: Treatment
Age: 21 and under
Trial IDs: ASCIST, NCI-2014-00275, NCT02130869
MRI-Guided Laser Heat Ablation in Treating Younger Patients with Brain Tumors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 3 to 21
Trial IDs: 201502062, NCI-2015-00403, NCT02372409
Start Over